ライフサイエンスコーパス: extended-spectrum

1 phylococcus aureus, 27% Pseudomonas, and 10% extended-spectrum beta-lactamase-producing bacteria, wit

2 0 allele, and the production of the CTX-M-15 extended spectrum beta-lactamase (ESBL).

3 We present an in-depth analysis of 178 extended-spectrum beta-lactamase (ESBL)-producing K. pne

4 rapy for suspected sepsis in Malawi in 2004, extended-spectrum beta-lactamase (ESBL)-E rapidly emerge

5 We used PCR to detect CTX-M in all 291 extended-spectrum cephalosporin-resistant gram-negative

6 1 (AmpC), 2b (TEM-1, TEM-2, and SHV-1), 2be (extended spectrum beta-lactamases [ESBLs] and K1), and 2

7 Forty-three wild-type (WT) strains, 42 extended-spectrum beta-lactamase (ESBL) producers, 18 ES

8 icillin-resistant Staphylococcus aureus [5], extended-spectrum beta-lactamase-producing Klebsiella pn

9 The assay was performed on 56 extended-spectrum-beta-lactamase (ESBL) E. coli isolates

10 ach of the three described isoenzymes and 69 extended-spectrum beta-lactamase-producing clinical isol

11 Specifically, the class A extended-spectrum beta-lactamases (ESBLs) and inhibitor-

12 The emergence of CTX-M class A extended-spectrum beta-lactamases poses a serious health

13 on travelers to the tropics annually acquire extended-spectrum beta-lactamase (ESBL)-producing Entero

14 th N1MS exhibiting superior activity against extended spectrum beta lactamase producers, despite dimi

15 High activity against extended-spectrum beta-lactamase, methicillin-resistant

16 ctivity of ceftazidime and cefpirome against extended-spectrum cephalosporin and Sme-1 containing car

17 platforms identified susceptibility against extended-spectrum cephalosporins and carbapenems in >90%

18 Although extended-spectrum beta-lactamases (ESBLs) hydrolyze ceph

19 of the strains were resistant to ampicillin, extended-spectrum cephalosporins, and aminoglycosides, i

20 ements for the hydrolysis of ceftazidime, an extended spectrum cephalosporin commonly used to treat s

21 and independent of AIRE, which may cover an extended spectrum of peripheral Ags in the thymus.

22 enerate peptide sequence tags (PSTs) from an extended spectrum graph.

23 The beta-lactamase of E. cloacae GC1, an extended spectrum mutant of the P99 enzyme, rapidly hydr

24 lelic mutations in KDSR are implicated in an extended spectrum of disorders of keratinization in whic

25 ch that uncovered the key role of IL-1 in an extended spectrum of immune dysregulatory conditions.

26 We show that BlaC is an extended spectrum beta-lactamase (ESBL) with high levels

27 nt serine carbapenemase), whereas PenI is an extended spectrum beta-lactamase.

28 of two enzymes, with only one possessing an extended spectrum of activity.

29 one of the patients had an infection with an extended spectrum beta-lactamase (ESBL) producing organi

30 one of the patients had an infection with an extended spectrum beta-lactamase-producing organism.

31 meolysin", ClyR, with robust activity and an extended-spectrum streptococcal host range against most

32 at are widely used in the clinic, such as an extended-spectrum beta-lactam antibiotic amoxicillin/cla

33 d urinary tract infection (UTI) caused by an extended-spectrum beta-lactamase (ESBL)-producing, multi

34 ized patients were more likely to develop an extended-spectrum beta-lactamase-producing Enterobacteri

35 atory have shown that the enzyme exhibits an extended-spectrum phenotype, with very high levels of pe

36 pneumoniae, and half of S. marcescens had an extended-spectrum B-lactamase phenotype.

37 Isavuconazole is an extended-spectrum triazole with in vitro activity agains

38 y in the Omega-loop may form the basis of an extended-spectrum activity of class C beta-lactamases ag

39 Probable transmission of an extended-spectrum-beta-lactamase-producing Escherichia c

40 re used to identify resistance integrons and extended spectrum beta-lactamase genes.

41 rovar Newport MDR-AmpC expressing TEM-1b and extended-spectrum beta-lactamase SHV-12 was isolated fro

42 s aureus (MRSA), Pseudomonas aeruginosa, and extended-spectrum beta-lactamases as ROs.

43 , the test accurately distinguished AmpC and extended-spectrum beta-lactamase production and differen

44 hicillin-resistant Staphylococcus aureus and extended-spectrum beta lactamase (ESBL) incidence were e

45 , carbapenem-resistant Escherichia coli, and extended-spectrum beta-lactamase-producing Klebsiella pn

46 nem-nonsusceptible (excluding ertapenem) and extended-spectrum cephalosporin-resistant Escherichia co

47 pled with restriction of fluoroquinolone and extended-spectrum beta-lactam use to control both the ma

48 alence of resistance to fluoroquinolones and extended-spectrum cephalosporins in clinical isolates of

49 with susceptibility to fluoroquinolones and extended-spectrum cephalosporins.

50 the implications of fluoroquinolone (FQ) and extended-spectrum cephalosporin plus cephamycin (AmpC) r

51 res, including complexes with inhibitors and extended-spectrum antibiotics, were determined by X-ray

52 and derepressed chromosomal beta-lactam and extended-spectrum beta-lactamase-producing Enterobacter

53 BL carbapenemases, AmpC beta-lactamases, and extended-spectrum beta-lactamases were tested.

54 especially extended-spectrum macrolides and extended-spectrum fluoroquinolones (P<.001 for all trend

55 of isolates were resistant to penicillin and extended-spectrum cephalosporins.

56 ng resistance to beta-lactam antimicrobials (extended-spectrum beta-lactamase [ESBL] positive or resi

57 zed by resistant intestinal bacteria such as extended-spectrum beta-lactamase-producing Enterobacteri

58 Newer beta-lactamases such as extended-spectrum beta-lactamases (ESBLs), transferable

59 ROs such as methicillin-resistant S. aureus, extended-spectrum beta-lactamase-producing, and carbapen

60 d by mixed resistant Gram-negative bacteria, extended-spectrum beta-lactamase-producing Enterobacteri

61 he benefits and safety of azithromycin-based extended-spectrum prophylaxis in women undergoing nonele

62 targeted pathogens (Acinetobacter baumannii, extended-spectrum beta-lactamase-producing Gram-negative

63 Clinical resistance to both extended-spectrum cephalosporins and beta-lactam-beta-la

64 e primary treatment for infections caused by extended-spectrum beta-lactamase (ESBL)-producing Klebsi

65 nt of nonbacteremic pyelonephritis caused by extended-spectrum beta-lactamase (ESBL)-producing organi

66 The continued rise in infections caused by extended-spectrum beta-lactamase (ESBL)-producing pathog

67 nce document focused on infections caused by extended-spectrum beta-lactamase-producing Enterobactera

68 Infections caused by extended-spectrum beta-lactamase-producing Enterobactera

69 the isolated bacteria, infections caused by extended-spectrum beta-lactamase-producing Enterobacteri

70 ad ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing Enterobacteri

71 ment considerations for infections caused by extended-spectrum beta-lactamase-producing organisms, Am

72 ary broad-spectrum beta-lactams, mediated by extended-spectrum beta-lactamase (ESBL) enzymes, is an i

73 pound also inhibits irreversibly the class C extended-spectrum GC1 beta-lactamase (IC(50) = 6.2 nM).

74 uencing survey was performed on carbapenem-, extended spectrum beta-lactam-, and cephalosporin-resist

75 stance against beta-lactams, cephalosporins (extended-spectrum beta-lactamase-producing type SHV-12),

76 ia coli strains producing well-characterized extended-spectrum, AmpC, or carbapenem-hydrolyzing beta-

77 bs on two selective culture media, CHROMagar extended-spectrum-beta-lactamase (ESBL) and vancomycin,

78 The structure of a chromosomal extended-spectrum beta-lactamase (ESBL) having the abili

79 ncing of previously uncharacterized clinical extended-spectrum beta-lactamase (ESBL)-producing Escher

80 Combined extended-spectrum beta-lactamase production (blaTEM-1 ge

81 ic residues, including those known to confer extended-spectrum activity.

82 c serine; the question of how they conferred extended-spectrum activity arose.

83 anic acid (CLAV) were also tested to confirm extended-spectrum beta-lactamase (ESBL) carriage.

84 Current prophylaxis regimens do not cover extended-spectrum beta-lactamase-producing Enterobacteri

85 rbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase (ESBL)-producing Entero

86 performed to assess their ability to detect extended-spectrum beta-lactamases (ESBLs) in members of

87 Eight (21.0%) of 38 labs failed to detect extended-spectrum cephalosporin or aztreonam resistance

88 rd CLSI disk diffusion methods for detecting extended-spectrum beta-lactamases (ESBLs) and with cefep

89 ening and confirmation methods for detecting extended-spectrum beta-lactamases (ESBLs) apply only to

90 sistant enterococcus, Clostridium difficile, extended-spectrum beta-lactamase-producing gram-negative

91 Approximately 1.0% of strains displayed extended-spectrum beta-lactamase (ESBL) activity.

92 Representative isolates from 10 distinct extended-spectrum beta-lactamase-producing strains of Kl

93 itivity patterns of the globally distributed extended-spectrum beta-lactamase CTX-M-15, and find thre

94 This drug pressure has driven extended-spectrum beta-lactamase (ESBL) gene acquisition

95 esistant Staphylococcus aureus) and ESBL-EC (extended-spectrum beta-lactamase-producing Escherichia c

96 increasingly associated with plasmid-encoded extended-spectrum beta-lactamases (ESBLs) and carbapenem

97 biotics arises from a chromosomally encoded, extended spectrum, class A beta-lactamase, BlaC.

98 rizontal dissemination of the genes encoding extended spectrum beta-lactamases (ESBLs) via conjugativ

99 se of nonrecommended antibiotics, especially extended-spectrum macrolides and extended-spectrum fluor

100 hvKP strains, 17% (5/29) of which expressed extended-spectrum beta-lactamase.

101 In a low prevalence area for extended spectrum betalactamases (ESBL) and multiresista

102 that have increased hydrolytic activity for extended-spectrum antibiotics such as ceftazidime.

103 ined using the revised CLSI breakpoints, for extended-spectrum-beta-lactamase (ESBL)-producing Escher

104 er chicken isolates carried genes coding for extended-spectrum SHV beta-lactamases.

105 Active surveillance culture for extended-spectrum beta-lactamase-producing Enterobacteri

106 talization were independent risk factors for extended-spectrum beta-lactamase-producing Enterobacteri

107 As routine testing of clinical isolates for extended-spectrum beta-lactamase (ESBL) production (scre

108 ught to assess the interest of screening for extended-spectrum beta-lactamase-producing Enterobacteri

109 Screening for extended-spectrum beta-lactamase-producing Enterobacteri

110 ts and used the double disk synergy test for extended-spectrum beta-lactamase-producing Enterobacteri

111 Clinical laboratories test for extended-spectrum beta-lactamases (ESBLs) for epidemiolo

112 To determine whether confirmatory tests for extended-spectrum beta-lactamase (ESBL) production in Es

113 phenotypes: fluoroquinolone-resistant (FQR), extended-spectrum cephalosporin-resistant (ESCR), carbap

114 ic structure of the Enterobacter cloacae GC1 extended-spectrum class C beta-lactamase, inhibited by a

115 ta-lactamases are one of the fastest growing extended-spectrum beta-lactamase (ESBL) families found i

116 h discordant isolates being primarily Guiana extended-spectrum (GES)-type producers.

117 e fatal cases, and two of these isolates had extended-spectrum beta-lactamase activity.

118 resistant gram-negative bacteria that harbor extended-spectrum beta-lactamases (ESBLs) are increasing

119 Escherichia coli, such as strains harboring extended-spectrum beta-lactamase (ESBL) genes, frequentl

120 resistant Acinetobacter baumannii (Hungary), extended-spectrum beta-lactamase-producing Escherichia c

121 riant TEM and SHV enzymes that can hydrolyze extended-spectrum antibiotics.

122 utations that permit the enzyme to hydrolyze extended-spectrum cephalosporins or to avoid inactivatio

123 Significant reductions were seen in extended-spectrum penicillins (p=0.0080), carbapenems (p

124 resistance to many cephalosporins including extended spectrum cephalosporins.

125 tiple antibiotic resistance genes, including extended spectrum beta-lactamases, for which therapeutic

126 istance to nonrelated antibiotics, including extended-spectrum beta-lactamases.

127 t to at least nine antimicrobials (including extended-spectrum cephalosporins), known as serotype New

128 ainst multidrug-resistant bacteria including extended-spectrum beta-lactamase (ESBL) and carbapenem-r

129 ith production of beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and carbapenem

130 he Netherlands, the prevalence of intestinal extended-spectrum beta-lactamase-producing Enterobacteri

131 biotic resistance evolution, we investigated extended-spectrum mutants of class C beta-lactamases, wh

132 t classes of multidrug-resistant bacteria is extended-spectrum beta-lactamase-producing bacteria (ESB

133 CTX-M extended-spectrum beta-lactamases (ESBLs) have emerged a

134 Currently, rising problems include CTX-M extended-spectrum beta-lactamases (ESBLs), plasmid-media

135 methoxy-ticarcillin) shows stability to most extended spectrum beta-lactamases, but is considered ina

136 ug-resistant Pseudomonas aeruginosa and most extended-spectrum beta-lactamase (ESBL)-producing Entero

137 Isavuconazole is a new extended-spectrum triazole with activity against yeasts,

138 d efficacy and safety of posaconazole, a new extended-spectrum triazole, as salvage therapy for IFIs

139 ivate penicillins and cephalosporins but not extended-spectrum antibiotics.

140 arisen multiple times in naturally occurring extended-spectrum TEM alleles, seven were recovered mult

141 cid substitutions in the naturally occurring extended-spectrum TEM alleles.

142 CTX-M enzymes are an emerging group of extended spectrum beta-lactamases (ESBLs) that hydrolyze

143 ly of beta-lactamases constitutes a group of extended spectrum resistance enzymes that hydrolyze peni

144 However, the rise of extended spectrum beta-lactamase (ESBL) producing bacter

145 cent study in Texas showed that up to 70% of extended-spectrum beta-lactamase (ESBL)-containing membe

146 Community-associated acquisition of extended-spectrum beta-lactamase- (ESBL) and carbapenema

147 mp inhibitors (PPIs) were rectal carriers of extended-spectrum beta-lactamase-producing Enterobacteri

148 Carriers of extended-spectrum beta-lactamase-producing Enterobacteri

149 One unreported case of extended-spectrum-beta-lactamase (ESBL)-producing Salmon

150 ly significant for postintervention cases of extended-spectrum beta-lactamase-producing organisms (P

151 t technologies permit the rapid detection of extended-spectrum beta-lactamase (bla(ESBL)) and Klebsie

152 impact of preenrichment on the detection of extended-spectrum beta-lactamase-producing Enterobacteri

153 function is valuable for the development of extended-spectrum NNRTIs.

154 The worldwide dissemination of extended-spectrum-beta-lactamase (ESBL)- and carbapenema

155 -driven model of the within-host dynamics of extended-spectrum beta-lactamase (ESBL) producing Entero

156 The emergence of extended-spectrum beta-lactamase (ESBL) and plasmid-medi

157 amase inhibitors has driven the evolution of extended-spectrum beta-lactamases (ESBLs) that possess t

158 iated with significantly higher frequency of extended-spectrum beta-lactamase-producing Enterobacteri

159 the Ser238 side chain to the oxime group of extended-spectrum antibiotics.

160 e of the G238S substitution in hydrolysis of extended-spectrum antibiotics.

161 substitution display increased hydrolysis of extended-spectrum antibiotics.

162 enzyme to provide an increased hydrolysis of extended-spectrum cephalosporins or an increased resista

163 Timely identification of extended-spectrum beta-lactamase (ESBL) bacteremia can i

164 Thus, changing the interpretation of extended-spectrum cephalosporins and aztreonam results f

165 y was to determine if the interpretations of extended-spectrum and advanced-spectrum cephalosporins (

166 The introduction of extended-spectrum cephalosporins and beta-lactamase inhi

167 LSI); and for isolates for which the MICs of extended-spectrum cephalosporins were > or =1 microg/ml

168 the pAmpC enzymes may yield similar MICs of extended-spectrum cephalosporins, many of which fall wit

169 Furthermore, a number of extended-spectrum beta-lactamases (ESBL) were identified

170 in 23 states to determine the occurrence of extended-spectrum beta-lactamase (ESBL) and AmpC beta-la

171 timicrobial resistance and the occurrence of extended-spectrum beta-lactamases (ESBLs) modulated by f

172 obacteriaceae colonization as a predictor of extended-spectrum beta-lactamase-producing Enterobacteri

173 lates were also screened for the presence of extended-spectrum beta-lactamase (ESBL) activity.

174 p. and Escherichia coli with the presence of extended-spectrum beta-lactamase (ESBL) and plasmid-medi

175 ceptibility testing revealed the presence of extended-spectrum beta-lactamase (ESBL) resistance.

176 The prevalence of extended-spectrum beta-lactamase (ESBL)-mediated resista

177 The worldwide prevalence of extended-spectrum beta-lactamase (ESBL)-producing Entero

178 The increasing prevalence of extended-spectrum beta-lactamase (ESBL)-producing Escher

179 t neonatal sepsis, with a high prevalence of extended-spectrum beta-lactamase-producing organisms.

180 ates included porin mutants and producers of extended-spectrum beta-lactamases (ESBLs), AmpCs, K1, an

181 rce of this resistance is from production of extended-spectrum (ES) beta-lactamases by bacteria.

182 20-week period were tested for production of extended-spectrum beta-lactamases (ESBLs) by the double-

183 The ICU acquisition rate of extended-spectrum beta-lactamase-producing Enterobacteri

184 Studies about transmission rates of extended-spectrum beta-lactamase (ESBL)-producing Entero

185 The determinants of the spread of extended-spectrum beta-lactamase-producing Escherichia c

186 nterobacteriaceae, mediated by the spread of extended-spectrum beta-lactamases (ESBLs), is a very ser

187 The emergence and spread of extended-spectrum beta-lactamases and carbapenemases amo

188 Strains of extended-spectrum beta-lactamase-producing Klebsiella pn

189 sistance in Enterobacteriaceae suggestive of extended-spectrum beta-lactamase (ESBL) production, carb

190 ped a deterministic model of transmission of extended-spectrum beta-lactamase-producing Escherichia c

191 cillin-tazobactam (PTZ) for the treatment of extended-spectrum beta-lactamase (ESBL) bacteremia is co

192 e exists with the detection and treatment of extended-spectrum beta-lactamase-producing organisms (Kl

193 producing CTX-M-15, the predominant type of extended-spectrum beta-lactamase (ESBL) associated with

194 ance have appeared in response to the use of extended-spectrum beta-lactam antibiotics (e.g., ceftazi

195 plant Patients) has provided pivotal data on extended-spectrum beta-lactamase (ESBL)-producing Entero

196 was defined by the isolation of at least one extended-spectrum beta-lactamase-producing Enterobacteri

197 roth microdilution (BMD) MIC of at least one extended-spectrum cephalosporin was >/=2 micro g/ml.

198 tance, defined as resistance to at least one extended-spectrum cephalosporin, one aminoglycoside, and

199 ally fluoroquinolone-resistant (FQ-R) and/or extended-spectrum beta-lactamase (ESBL)-producing, has e

200 o >128 micro g/ml and the MICs for the other extended-spectrum cephalosporins were highly variable.

201 The VITEK 2 and Phoenix extended-spectrum beta-lactamase (ESBL) detection system

202 lasmid-mediated quinolone resistance (PMQR), extended-spectrum beta-lactamases (ESBL) and AmpC beta-l

203 ia coli and Klebsiella pneumoniae possessing extended-spectrum class A beta-lactamases (ESBLs) contin

204 screened by the MicroScan system as possible extended-spectrum-beta-lactamase (ESBL)-producing organi

205 Sensitivity and specificity of prior extended-spectrum beta-lactamase-producing Enterobacteri

206 Strains of Klebsiella frequently produce extended-spectrum beta-lactamases, and infections with t

207 a, especially Klebsiella pneumoniae, produce extended-spectrum beta-lactamases (ESBLs) as an antibiot

208 . 68.6%) and Enterobacteriaceae that produce extended-spectrum beta-lactamases (82.4% vs. 75.0%).

209 Gram-negative bacteria that produce extended-spectrum- and metallo-beta-lactamases are being

210 d 109 (80%) isolates, respectively, produced extended-spectrum beta-lactamases (ESBL).

211 trols consisted of 50 isolates that produced extended-spectrum beta-lactamases (ESBLs), AmpCs (includ

212 hia coli, Escherichia coli (ESBL) (producing extended spectrum beta-lactamases) and Morganella morgan

213 sed by multidrug-resistant strains producing extended-spectrum beta-lactamases and/or carbapenemases.

214 stance mechanisms, including those producing extended-spectrum beta-lactamase enzymes.

215 Other residues promoting extended-spectrum activity in K1 include the side-chains

216 l receiving standard antibiotic prophylaxis, extended-spectrum prophylaxis with adjunctive azithromyc

217 Rather, extended spectrum activities can emerge from the backgro

218 Reduced extended-spectrum cephalosporin susceptibility is predom

219 The majority of studies reported extended-spectrum beta-lactamase (ESBL)-producing Entero

220 Studies reporting extended-spectrum beta-lactamase-producing Enterobacteri

221 lving a combination of multidrug resistance, extended spectrum beta-lactamase production and azithrom

222 chia coli (E. coli) and antibiotic-resistant extended-spectrum beta-lactamase-producing (ESBL) E. col

223 robacteriaceae (CRE), blaNDM-1, and selected extended-spectrum beta-lactam (ESBL) resistant bacteria

224 istically demonstrates resistance to several extended-spectrum antimicrobial agents.

225 nella enterica serovar Typhi isolate showing extended spectrum beta-lactamase (ESBL) production in th

226 herichia coli DH10B strains bearing bla(SHV) extended-spectrum and inhibitor-resistant beta-lactamase

227 he maintenance of a plasmid bearing a single extended-spectrum B-lactamase (ESBL) gene (bla(CTX-M-14)

228 categories: narrow spectrum, broad spectrum, extended spectrum, and agents targeted for protection.

229 of prior colonization to predict subsequent extended-spectrum beta-lactamase-producing Enterobacteri

230 teus mirabilis with an ertapenem-susceptible extended-spectrum-beta-lactamase (ESBL)-positive phenoty

231 r case, and literature review, suggests that extended-spectrum penicillins, tetracycline, and trimeth

232 The extended spectrum of mtDNA rearrangements in single cell

233 These structural differences may explain the extended spectrum activity of GC1 against this class of

234 When used for the extended spectrum of endothelial pathologies, DMEK prove

235 nother mutant of the P99 beta-lactamase, the extended spectrum GC1 enzyme, also has space available f

236 The extended-spectrum cephalosporin resistance in these noso

237 The extended-spectrum cephalosporins--cefixime and ceftriaxo

238 The extended-spectrum triazoles were most active in the Asia

239 phalosporins, we found genes that encode the extended-spectrum beta-lactamases CTX-M-2, CTX-M-14, and

240 rolytic activity of the G238S enzyme for the extended-spectrum antibiotics cefotaxime and ceftazidime

241 wild-type level activity or greater for the extended-spectrum cephalosporin ceftazidime and the mono

242 nicillins and cephalosporins, except for the extended-spectrum cephalosporins.

243 Although new enzymes in the extended-spectrum beta-lactamase (ESBL) families are fre

244 Two are found in the extended-spectrum beta-lactamases most frequently identi

245 Additionally, ARGs, including the extended-spectrum ss-lactam- and aminoglycoside-resistan

246 ylation (k(2)) and deacylation (k(3)) of the extended-spectrum beta-lactamase were enhanced.

247 tween the restriction digest patterns of the extended-spectrum beta-lactamase-encoding plasmids were

248 All of the extended-spectrum beta-lactamases were encoded by self-t

249 spergillus spp. was observed for each of the extended-spectrum triazoles and varied by species over t

250 te on the enzyme rather than directly to the extended-spectrum antibiotic.

251 producers and reported the results with the extended-spectrum cephalosporins and aztreonam as resist

252 xime, ceftazadime, and aztreonam, i.e., the "extended-spectrum" phenotype.

253 rams antibiotic disks, the fraction of these extended-spectrum beta-lactamase (ESBL)-producing isolat

254 Autoantibodies of this extended spectrum may enhance autoimmune serological tes

255 apbpF DeltaponA mutant and triple mutants to extended spectrum cephalosporins (ceftriaxone and cefepi

256 gonorrhoeae with decreased susceptibility to extended spectrum cephalosporins raises the prospect of

257 The failure was attributed to extended-spectrum beta-lactamase (ESBL) acquisition by t

258 enes fell within the susceptible category to extended-spectrum cephalosporins, raising concern over c

259 ce of community-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing Escher

260 e care unit (ICU)-acquired infections due to extended-spectrum beta-lactamase-producing Enterobacteri

261 ment of bloodstream infections (BSIs) due to extended-spectrum beta-lactamase-producing Enterobacteri

262 halosporin and monobactam antibiotics due to extended-spectrum beta-lactamases (ESBLs) has resulted i

263 ibiotics have been found to be equivalent to extended-spectrum (antipseudomonal) agents in preventing

264 nd categorize evidence for human exposure to extended-spectrum beta-lactamase-producing Enterobacteri

265 Resistance of Neisseria gonorrhoeae to extended-spectrum cephalosporins (ESCs) has become a maj

266 alence and dynamics of resistance markers to extended-spectrum cephalosporins, macrolides, and fluoro

267 eumoniae that exhibited nonsusceptibility to extended-spectrum cephalosporins were detected.

268 rolytic spectrum for bacterial resistance to extended-spectrum antibiotics.

269 Resistance to extended-spectrum beta-lactam antibiotics has led to a g

270 robacter spp. and also mediate resistance to extended-spectrum cephalosporins and aztreonam in additi

271 -negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam.

272 -negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam.

273 (ESBL-type enzymes that confer resistance to extended-spectrum cephalosporins and carbapenems) presen

274 e in Enterococcus faecium, and resistance to extended-spectrum cephalosporins in Klebsiella pneumonia

275 Resistance to extended-spectrum cephalosporins is associated with clin

276 Enterobacteriaceae can confer resistance to extended-spectrum cephalosporins, aztreonam, and penicil

277 ceptibility testing, 9.18% were resistant to extended-spectrum cephalosporins, 28.22% to fluoroquinol

278 eae strains with decreased susceptibility to extended-spectrum cephalosporins (ESCs).

279 and a control strain that was susceptible to extended-spectrum cephalosporins to 38 laboratories in C

280 ance to carbapenems, which are used to treat extended-spectrum beta-lactamase (ESBL)-producing bacter

281 well as the D49A and F142A mutants, with two extended spectrum beta-lactamases (the G238S and the E10

282 plasmid-borne AmpC gene (bla CMY-42) and two extended-spectrum beta-lactamase genes (bla CTX-M-15 and

283 oacae bloodstream isolates produced SHV-type extended-spectrum beta-lactamases (ESBLs) in addition to

284 In 45 isolates, 49 previously unrecognized extended-spectrum beta-lactamase or plasmid AmpC targets

285 A), vancomycin-resistant enterococcus (VRE), extended-spectrum cephalosporin resistance in Enterobact

286 ancomycin-resistant Enterococcus spp. (VRE), extended-spectrum beta-lactamase-producing organisms (ES

287 isolates and three Klebsiella isolates) were extended-spectrum beta-lactamase producers.

288 We describe two patients in whom extended-spectrum beta-lactamase (ESBL)-producing Escher

289 rm risks of bloodstream infection (BSI) with extended spectrum beta-lactamase-producing Enterobacteri

290 ns of non-Salmonella Enterobacteriaceae with extended spectrum beta-lactamase (ESBL) or fluoroquinolo

291 vided data on ICU-acquired colonization with extended-spectrum beta-lactamase-producing Enterobacteri

292 etermine the risk of stool colonization with extended-spectrum cephalosporin-resistant gram-negative

293 ted pneumonia, 40 (6.8%) were colonized with extended-spectrum beta-lactamase-producing Enterobacteri

294 previously detected as being colonized with extended-spectrum beta-lactamase-producing Enterobacteri

295 of KPC-producing E. coli when compared with extended-spectrum beta-lactamase-producing E. coli.

296 italized patients colonized or infected with extended-spectrum beta-lactamase-producing Escherichia c

297 ization is a risk factor for infections with extended-spectrum beta-lactamase (ESBL)-producing organi

298 coli and Klebsiella pneumoniae isolates with extended-spectrum beta-lactamases (ESBLs) or AmpC cephal

299 ion at C12 led to 12-epi-pleuromutilins with extended-spectrum antibacterial activity, including acti

300 the colonization of the digestive tract with extended-spectrum beta-lactamase-producing Enterobacteri